Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joaquin Fuentes

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Pediatric Research|March 26, 2021
Tackling healthcare access barriers for individuals with autism from diagnosis to adulthoodNatasha Malik-Soni, Andrew Shaker, Helen Luck, et al.
Autism Research : Official Journal of the International Society for Autism Research|October 5, 2023
Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studiesJoaquin Fuentes, Mara Parellada, Christina Georgoula, et al.
Child Psychiatry and Human Development|March 16, 2022
A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline CharacteristicsChristina Georgoula, Maite Ferrin, Bozena Pietraszczyk-Kedziora, et al.
European Child & Adolescent Psychiatry|May 11, 2020
The ASDEU autism prevalence study in northern SpainJoaquin Fuentes, Ane Basurko, Irma Isasa, et al.
Journal of Autism and Developmental Disorders|November 5, 2020
Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)Véronique Crutel, Estelle Lambert, Pierre-François Penelaud, et al.
Journal of Autism and Developmental Disorders|January 10, 2021
Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)Véronique Crutel, Estelle Lambert, Pierre-François Penelaud, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|January 19, 2011
Against le packing: a consensus statementDavid Amaral, Sally J Rogers, Simon Baron-Cohen, et al.
Autism : the International Journal of Research and Practice|April 29, 2015
Use of early intervention for young children with autism spectrum disorder across EuropeErica Salomone, Štěpánka Beranová, Frédérique Bonnet-Brilhault, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Pediatric Research|March 26, 2021
Tackling healthcare access barriers for individuals with autism from diagnosis to adulthoodNatasha Malik-Soni, Andrew Shaker, Helen Luck, et al.
Autism Research : Official Journal of the International Society for Autism Research|October 5, 2023
Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studiesJoaquin Fuentes, Mara Parellada, Christina Georgoula, et al.
Child Psychiatry and Human Development|March 16, 2022
A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline CharacteristicsChristina Georgoula, Maite Ferrin, Bozena Pietraszczyk-Kedziora, et al.
European Child & Adolescent Psychiatry|May 11, 2020
The ASDEU autism prevalence study in northern SpainJoaquin Fuentes, Ane Basurko, Irma Isasa, et al.
Journal of Autism and Developmental Disorders|November 5, 2020
Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)Véronique Crutel, Estelle Lambert, Pierre-François Penelaud, et al.
Journal of Autism and Developmental Disorders|January 10, 2021
Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)Véronique Crutel, Estelle Lambert, Pierre-François Penelaud, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|January 19, 2011
Against le packing: a consensus statementDavid Amaral, Sally J Rogers, Simon Baron-Cohen, et al.
Autism : the International Journal of Research and Practice|April 29, 2015
Use of early intervention for young children with autism spectrum disorder across EuropeErica Salomone, Štěpánka Beranová, Frédérique Bonnet-Brilhault, et al.
Pageof 2